Searched over 200M research papers
4 papers analyzed
These studies suggest that the brand name of sitagliptin is effective in lowering blood sugar levels in type 2 diabetes, with weight-neutral effects and low risk of hypoglycemia.
20 papers analyzed
Sitagliptin is a widely used medication for the treatment of type 2 diabetes mellitus. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones, thereby enhancing insulin secretion and inhibiting glucagon release when blood glucose levels are elevated .
Sitagliptin is marketed under several brand names globally. The most commonly recognized brand name is Januvia®, which is produced by Merck Pharmaceuticals . Additionally, sitagliptin is also available under other brand names such as Glactiv®, Tesavel®, and Xelevia™ in various regions .
Sitagliptin has been extensively studied and shown to be effective in improving glycemic control in patients with type 2 diabetes. It is used both as monotherapy and in combination with other antihyperglycemic agents. Clinical trials have demonstrated significant reductions in glycosylated hemoglobin (HbA1c) levels, fasting plasma glucose (FPG), and postprandial glucose (PPG) levels with sitagliptin treatment .
The medication is generally well tolerated, with a low risk of hypoglycemia, especially when not used in combination with other agents that may cause hypoglycemia, such as sulfonylureas or insulin. Sitagliptin is also noted for being weight-neutral, which is a significant advantage for many patients .
Sitagliptin, primarily known under the brand name Januvia®, is a potent and selective DPP-4 inhibitor used in the management of type 2 diabetes. It is also marketed under the names Glactiv®, Tesavel®, and Xelevia™. The drug has proven efficacy in lowering blood glucose levels and is generally well tolerated, making it a valuable option for patients with type 2 diabetes.
Most relevant research papers on this topic